Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 3 3Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mastocytosis 1Liver Neoplasms 1Gastroenteropancreatic Neuroendocrine Tumors 1GATA2 Deficiency 1Colorectal Neoplasms 1Advanced Solid Tumor 1

Interventions

Carboplatin 7Gemcitabine 5130-nm albumin-bound paclitaxel 3Paclitaxel 2olaparib 1eryaspase 1camrelizumab 1Injections 1Erythrocyte Count 1Epirubicin 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1Cisplatin 1Capecitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Triple Negative Breast Neoplasms × Injections × Clear all
NCT07544056 2026-04-22

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

BeBetter Med Inc

Phase 2/3 Not yet recruiting
446 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡